2020
Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial
Pandya B, Qi C, Yang H, Garnham A, Shah M, Zeidan A. Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial. Blood 2020, 136: 7. DOI: 10.1182/blood-2020-136184.Peer-Reviewed Original ResearchCR/CRhAcute myeloid leukemiaSalvage chemotherapyADMIRAL trialOverall survivalAML patientsClinical benefitMore patientsSurvival outcomesMyeloid leukemiaAstellas PharmaComplete remission/complete remissionConfidence intervalsTyrosine kinase 3 mutationsLonger median overall survivalDismal survival outcomesIncomplete hematologic recoveryIncomplete platelet recoveryMedian overall survivalSuperior clinical benefitSignificant clinical benefitAbsolute rate differenceSelective FLT3 inhibitorHigh response rateEvent rate differenceStreamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes
Zeidan A, Gilligan A, Gautam S, Grinblatt D, Elsouda D, Sullivan L, Pandya B. Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes. Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-136366.Peer-Reviewed Original ResearchFLT3 tyrosine kinase inhibitorsAcute myeloid leukemiaTyrosine kinase inhibitorsMedian overall survivalOverall survivalFLT3 mutation statusTreatment patternsR settingTKI useAML patientsFMS-like tyrosine kinase 3 (FLT3) mutationsMutation statusDiagnosis of AMLTyrosine kinase 3 mutationsElectronic medical record dataEligible adult patientsHigh-intensity chemotherapyOngoing retrospective studyPost-treated patientsAstellas PharmaRetrospective cohort studySystemic anticancer therapyKaplan-Meier analysisReal-world treatmentTesting trends
2019
Streamline - Study of Relapse or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study
Zeidan A, Gilligan A, Gautam S, Hu N, Grinblatt D, Pandya B. Streamline - Study of Relapse or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study. Blood 2019, 134: 5082. DOI: 10.1182/blood-2019-123535.Peer-Reviewed Original ResearchR AMLHigh-intensity chemotherapyLow-intensity chemotherapyBest supportive careAcute myeloid leukemiaFLT3 mutational statusMajority of ptsElectronic medical recordsFLT3 inhibitorsDifferent anticancer therapiesMutational statusCohort studyInitial diagnosisEMR databaseFMS-like tyrosine kinase 3 (FLT3) mutationsTyrosine kinase 3 mutationsStudy periodSubset of ptsObservational cohort studyRetrospective cohort studyClinical research nursesAnticancer therapyConfirmation of diagnosisImportant therapeutic innovationsInitial AML diagnosis